JNJ vs MSFT: Johnson & Johnson and Microsoft compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Microsoft is the larger company, worth $4.14T, about 6.5 times Johnson & Johnson.
- Microsoft grew revenue faster over the last year (+17.8% vs +6.6%).
- On earnings, Johnson & Johnson is the cheaper stock (30.5x vs 33.2x).
- Microsoft's price assumes faster free cash flow growth: about 20% a year, against 11% for Johnson & Johnson (reverse DCF).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | JNJ | MSFT |
|---|---|---|
| Market cap | $632.9B | $4.14T |
| Share price | $261.44 | $535.07 |
| Revenue (last fiscal year) | $94.2B | $331.8B |
| Free cash flow (last fiscal year) | $19.7B | $67.0B |
| Revenue growth, last year | +6.6% | +17.8% |
| Revenue growth per year, last 5 fiscal years | +4.6% | +13.7% |
| Operating margin | — | 46.8% |
| Net margin | 21.5% | 40.3% |
| Return on equity | 24.8% | 30.2% |
| P/E (trailing) | 30.5x | 33.2x |
| Price / free cash flow | 32.1x | 57.8x |
| EV / EBITDA | 19.4x | 19.1x |
| FCF growth the price implies | 11.2% | 19.8% |
| Dividend yield | 2.0% | 0.66% |
| Debt / equity | 1.37x | 0.71x |
| Fundamental grade | C | B |
| Superinvestors holding it | 17 | 33 |
| Insider purchases, last 12 months | 10 | 10 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Johnson & Johnson
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $78.7B | $19.8B | — |
| 2022 | $80.0B | $17.2B | — |
| 2023 | $85.2B | $18.2B | — |
| 2024 | $88.8B | $19.8B | — |
| 2025 | $94.2B | $19.7B | — |
Microsoft
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2022 | $198.3B | $65.1B | 42.1% |
| 2023 | $211.9B | $59.5B | 41.8% |
| 2024 | $245.1B | $74.1B | 44.6% |
| 2025 | $281.7B | $71.6B | 45.6% |
| 2026 | $331.8B | $67.0B | 46.8% |
Where the revenue comes from
Johnson & Johnson · by segments, 2025
Innovative Medicine$60.4B64%
MedTech$33.8B36%
Microsoft · by segments, 2026
Productivity and Business Processes$140.0B42%
Intelligent Cloud$137.8B42%
More Personal Computing$54.1B16%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open JNJ in InvestinglyQuestions
Which is bigger, Johnson & Johnson or Microsoft?
Microsoft (MSFT), at $4.14T against $632.9B.
Is JNJ or MSFT cheaper?
By trailing P/E, Johnson & Johnson (30.5x) is cheaper than Microsoft (33.2x). A lower multiple can also mean the market expects less growth.
Which grows faster, JNJ or MSFT?
Microsoft: revenue grew +17.8% over the last year, against +6.6%.
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.